Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Sep 29;10(1):16018.
doi: 10.1038/s41598-020-72538-x.

Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells

Yosuke Ida #  1 , Fumihito Hikage #  2 , Araya Umetsu  1 , Haruka Ida  1 , Hiroshi Ohguro  1
Affiliations
Comparative Study

Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells

Yosuke Ida et al. Sci Rep. .

Abstract

2D and 3D cultures of 3T3-L1 cells were employed in a study of the effects of Omidenepag (OMD), interacting with a non-prostanoid EP2 receptor, on adipogenesis. Upon adipogenesis, the effects on lipid staining, the mRNA expression of adipogenesis-related genes (Pparγ, CEBPa, Ap2, and Glut4) and the extracellular matrix (ECM) including collagen type 1, 4 and 6, and fibronectin, and the size and physical property of 3D organoids were compared between groups that had been treated with EP2 agonists (butaprost and OMD) and PGF2α. Upon adipogenesis, these significantly suppressed lipid staining and the mRNA expression of related genes. EP2 agonists and PGF2α influenced the mRNA expression of ECM in different manners, and these effects were also different between 2 and 3D cultures. Examining the physical properties by a microsqueezer indicated that the solidity of the 3D organoids became significantly lowered upon adipogenesis and these effects were not affected by EP2 agonists. In contrast, 3D organoid stiffness was markedly enhanced by the presence of PGF2α. These observations indicate that EP2 agonists affect the adipogenesis of 3T3-L1 cells in different manners, as compared to PGF2α, suggesting that OMD may not induce PGF2α related orbital fat atrophy, called the deepening of the upper eyelid sulcus (DUES).

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Effects of PGF2α, butaprost (Buta) or omidenepag (OMD) on adipogenesis of 2D cultured 3T3-L1 cells.
Figure 2
Figure 2
Effects of PGF2α, butaprost (Buta) or omidenepag (OMD) on ECM expression in 2D cultured 3T3-L1 cells.
Figure 3
Figure 3
Effects of PGF2α, butaprost (Buta) or omidenepag (OMD) on sizes of 3T3-L1 3D organoid during their adipogenesis.
Figure 4
Figure 4
Representative confocal images of lipid staining (BODIPY) of the 3D organoids under various conditions.
Figure 5
Figure 5
mRNA expression of adipogenesis related genes including Pparγ, Cebpα, Ap2 or Glut4, of the 3D organoids under various conditions.
Figure 6
Figure 6
qPCR analyses of the gene expression of ECM in 3D organoids.
Figure 7
Figure 7
Physical solidity of 3D organoids.
See this image and copyright information in PMC

References

    1. Impagnatiello F, et al. Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma. Br. J. Pharmacol. 2019;176:1079–1089. doi: 10.1111/bph.14328. - DOI - PMC - PubMed
    1. Camras CB, Bito LZ, Eakins KE. Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits. Invest. Ophthalmol. Vis. Sci. 1977;16:1125–1134. - PubMed
    1. Cheema A, Chang RT, Shrivastava A, Singh K. Update on the medical treatment of primary open-angle glaucoma. Asia Pac. J. Ophthalmol. (Phila) 2016;5:51–58. doi: 10.1097/APO.0000000000000181. - DOI - PubMed
    1. Schwenn O, Heckmann B, Guzy C, Miller PJ. Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study. BMC Ophthalmol. 2010;10:21. doi: 10.1186/1471-2415-10-21. - DOI - PMC - PubMed
    1. Susanna R, Jr, Giampani J, Jr, Borges AS, Vessani RM, Jordao ML. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology. 2001;108:259–263. doi: 10.1016/s0161-6420(00)00495-4. - DOI - PubMed

Publication types